Lowenstein Sandler represented RTW Investments, LP (“RTW”) as an investor in the $80 million financing round in Jade Biosciences, Inc. ("Jade"), a biotechnology company dedicated to developing best-in-class therapies for patients living with autoimmune diseases. The financing was led by Fairmount and Venrock Healthcare Capital Partners with participation by Deep Track Capital, Driehaus Capital Management, Franklin Templeton, and Braidwell LP.
RTW is an investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
This strategic investment by RTW will enable Jade to accelerate its development of targeted therapies aimed at addressing critical unmet medical needs in inflammation and immunology. This financial backing not only supports Jade's strategic plans but also reinforces its capacity to push forward with its transformative therapy projects, under the new leadership of Dr. Andrew King, aiming to redefine the standard of care in the sector.
The Lowenstein deal team included Abraham J. Kwon and Storme McKop.
